Navigation Links
Valeant Announces Pricing of Senior Notes
Date:3/3/2011

MISSISSAUGA, Ontario, March 3, 2011 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) (the "Company") announced today that Valeant Pharmaceuticals International ("Valeant"), its wholly owned indirect subsidiary, has priced its previously announced offering of senior unsecured notes, which consists of $950 million aggregate principal amount of 6.500% Senior Notes due 2016 and $550 million aggregate principal amount of 7.250% Senior Notes due 2022 (collectively, the "Notes"). The offering is expected to close on or about March 8, 2011.

The Notes will not be registered under the Securities Act of 1933, as amended (the "Securities Act"), or any state securities law and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the Securities Act and applicable state securities laws. The Notes will be offered in the United States only to qualified institutional buyers under Rule 144A of the Securities Act and outside the United States under Regulation S of the Securities Act. The Notes have not been and will not be qualified for sale to the public by prospectus under applicable Canadian securities laws and, accordingly, any offer and sale of the securities in Canada will be made on a basis which is exempt from the prospectus requirements of such securities laws.

The Notes will be guaranteed by the Company and each of the Company's subsidiaries (other than Valeant) that is a guarantor under Valeant's other senior notes.

Valeant intends to use the net proceeds from the offering of the Notes to prepay the amounts outstanding under its term loan A facility (and cancel the undrawn senior secured revolving credit facility); to fund the $275 million repurchase of shares of the Company's common shares from ValueAct Capital Master Fund, L.P. pursuant to the terms of a recently announ
'/>"/>

SOURCE Valeant Pharmaceuticals International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Valeant to Acquire Polish Products
2. GSK and Valeant Announce New U.S. FDA PDUFA Goal Date for Ezogabine
3. Valeant and Biovail Announce Results of Special Meetings of Shareholders
4. Valeant Pharmaceuticals Announces Redemption and Defeasance of 7.625% Senior Notes Due 2020 and 8.375% Senior Notes Due 2016
5. Valeant Pharmaceuticals Announces That Alexza Pharmaceuticals Has Received a Complete Response Letter for AZ-004 (Staccato® Loxapine) Inhalation Aerosol NDA
6. Valeant Pharmaceuticals Reports 2010 Third Quarter Financial Results
7. Valeant Declares Special Dividend and Plans to Create a Special Dividend Reinvestment Plan
8. Valeant Announces Pricing of Senior Notes
9. Valeant Pharmaceuticals Announces Appointment of Robert A. Ingram and Resignation of William M. Wells as Chairman
10. Valeant Pharmaceuticals Appoints Philip W. Loberg as Interim CFO
11. Regulatory Update - GSK and Valeant Receive Positive Opinion in Europe From the CHMP for Trobalt (Retigabine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... , Oct. 2, 2014   West Pharmaceutical ... global leader in innovative solutions for injectable drug administration, ... operations to include a new site in ... packaging components for insulin injector cartridges and other high-value ... pharmaceutical and biotech customers. Once operational, this new site ...
(Date:10/1/2014)... , Oct. 1, 2014   Plexus ... provider of Anesthesia Information Management Systems (AIMS), announced ... LLC , a wholly owned subsidiary of Quality ... information systems and connectivity solutions.  ... http://photos.prnewswire.com/prnh/20140930/149407 This partnership extends ...
(Date:10/1/2014)... NeuroCall, Inc., ("NeuroCall") announced today that it recently received ... Dr. Ricardo Garcia-Rivera , Founder and Chief Medical ... our quality of service has been recognized by The ... and continuity of care to patients of our expanding ... States ." NeuroCall currently provides ...
Breaking Medicine Technology:West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 2West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 3West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 4West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 5Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 2Plexus IS' Anesthesia Documentation Solution Strengthens NextGen Healthcare Product Offering 3NeuroCall Awarded Joint Commission Accreditation 2
... , MINNEAPOLIS , Feb. 4 ... of state-of-the-art cardiac surgery products and services, today announced that it will ... , after the market close on Monday, March 1, 2010 . ... March 1, 2010 at 5:00 p.m. Eastern Time ( ...
... PITTSBURGH , Feb. 4 Mylan Inc. (Nasdaq: ... in connection with the filing of an Abbreviated New Drug Application ... Besylate and Atorvastatin Calcium Tablets 2.5/10 mg, 2.5/20 mg, 2.5/40 mg, ... mg, 10/40 and 10/80 mg. This product is the generic version ...
Cached Medicine Technology:ATS Medical Announces Fourth Quarter 2009 Earnings Release Date and Conference Call 2ATS Medical Announces Fourth Quarter 2009 Earnings Release Date and Conference Call 3Mylan Confirms First-to-File Patent Challenge Relating to Caduet(R) 2
(Date:10/2/2014)... October 02, 2014 Robins & ... the Associated Builders and Contractors (ABC) of Alabama. ... tonight’s banquet held at Sheraton Birmingham Hotel., ... Healthcare $10 Million to $25 Million, Obelisk Award ... Clinic, Federal Government $10 Million to $25 Million, ...
(Date:10/2/2014)... Maureen Salamon ... News) -- Middle-aged women with a neurotic personality style ... developing Alzheimer,s disease, new research suggests. Tracking 800 ... those who were most anxious, jealous and moody -- ... stress had double the risk of developing Alzheimer,s compared ...
(Date:10/2/2014)... HealthDay Reporter WEDNESDAY, Oct. 1, 2014 ... isn,t reduced by breast-feeding. Nor will delaying the introduction of ... diet help prevent celiac disease. Those are the ... 2 New England Journal of Medicine . The ... avoid celiac disease if mothers breast-feed their babies and introduce ...
(Date:10/1/2014)... of Adelaide have developed a model that could help ... from treatment - from their very first psychotic episode. ... factors, including clinical symptoms, cognitive abilities, MRI scans of ... , Speaking in the lead up to World Mental ... Psychiatry , Professor Bernhard Baune , says the ...
(Date:10/1/2014)... co-funded by the Engineering and Physical Sciences Research ... the UK,s vital industrial control systems which run, ... grid, and the rail network. , The ... hackers or malware infiltrating the systems behind our ... in Trustworthy Industrial Control Systems (RITICS), based at ...
Breaking Medicine News(10 mins):Health News:Robins & Morton wins nine awards from Associated Builders and Contractors 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 2Health News:Jealous, Moody Women May Face Higher Alzheimer's Risk, Study Says 3Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 2Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 3Health News:Predicting the future course of psychotic illness 2Health News:£2.5 million to recognize and reduce cyber-attack threats to critical infrastructure 2
... new study in the Annals,of Internal Medicine adds ... patients for the bacterium MRSA (methicillin-resistant,Staphylococcus aureus) is ... The study, published yesterday, resulted in a 70%,reduction ... in the,Evanston Northwestern Healthcare System, located near Chicago., ...
... 2008, WASHINGTON, March 18 Following is the,National ... The Bulletin, which is free of charge and available ... the latest issues and news,affecting people with disabilities. To ... click on Online mailing list archives,select NCD-NEWS-L, click on ...
... One of the nations oldest and most respected non-profit ... fellowships to underrepresented minority students and scientists to attend ... 5-9. The American Physiological Society (APS), which administers the ... travel awards. , APS administers the program with financial ...
... and SHANGHAI, China, March 18 ,Flagship Global Health, ... Limited (CHC), listed on the Stock Exchange of ... a strategic alliance to,jointly utilize their resources and ... leading insurance companies, including,China Ping An and China ...
... safety tests and is relatively painless , , TUESDAY, March 18 ... veins proved safe in patients, according to the results of ... found that use of injectable Varisolve microfoam didn,t cause any ... patients with a common heart defect. , Since 1997, ...
... HILL, N.C., March 18 The Internet has ... leaders,haven,t lost sight of the value of an ... a relationship and high performing sales,groups -- irrespective ... of their time identifying and addressing existing clients, ...
Cached Medicine News:Health News:Evanston-Northwestern Study Proves Effectiveness of MRSA Screening to Reduce Hospital Infections 2Health News:National Council on Disability Monthly Bulletin for February, 2008 2Health News:National Council on Disability Monthly Bulletin for February, 2008 3Health News:National Council on Disability Monthly Bulletin for February, 2008 4Health News:52 minority scientists receive travel fellowships to Experimental Biology 2008 2Health News:52 minority scientists receive travel fellowships to Experimental Biology 2008 3Health News:Flagship Global Health and China HealthCare Holdings Form Strategic Alliance 2Health News:Flagship Global Health and China HealthCare Holdings Form Strategic Alliance 3Health News:New Foam Treatment for Varicose Veins 2Health News:High Performing Sales Forces Follow Same Path to Excellence 2
AST (SGOT) R1 + R2. Automated analyzer test kits....
Intended for the quantitative determination of aspartate aminotransferase activity in serum or plasma. Reaction: Kinetic. Wavelength: 340 nm. Linearity: 268 U/L at 30C. Two vials, dry powder reagents...
The Midas II Stainer is an automated slide stainer designed for use in hematology and microbiology laboratories....
... TST 40 tissue stainer is an "assembly-line ... in histology and cytology laboratories. Programmable continuous ... stains big quantities of slides in short ... in combination with a continuous working principle ...
Medicine Products: